Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
Status:
Recruiting
Trial end date:
2024-06-28
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international
multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with
NASH/NAFLD